Biophytis S.A. (ALBPS.PA)
EUR 0.33
(0.92%)
EUR 0.33
(0.92%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.93 Million EUR | -45.71% |
| 2022 | 21.98 Million EUR | -39.37% |
| 2021 | 36.26 Million EUR | 33.27% |
| 2020 | 27.21 Million EUR | 53.97% |
| 2019 | 17.67 Million EUR | -19.17% |
| 2018 | 21.86 Million EUR | -15.74% |
| 2017 | 25.94 Million EUR | 209.15% |
| 2016 | 8.39 Million EUR | -37.91% |
| 2015 | 13.51 Million EUR | 3393.95% |
| 2014 | 386.85 Thousand EUR | -38.38% |
| 2013 | 627.76 Thousand EUR | -48.11% |
| 2012 | 1.2 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 8.71 Million EUR | 0.0% |
| 2024 Q1 | 8.71 Million EUR | -26.99% |
| 2023 FY | 11.93 Million EUR | -45.71% |
| 2023 Q1 | 14.61 Million EUR | -33.54% |
| 2023 Q2 | 14.61 Million EUR | 0.0% |
| 2023 Q4 | 11.93 Million EUR | -0.2% |
| 2023 Q3 | 11.96 Million EUR | -18.16% |
| 2022 Q2 | 33.88 Million EUR | 0.0% |
| 2022 Q4 | 21.98 Million EUR | 0.0% |
| 2022 FY | 21.98 Million EUR | -39.37% |
| 2022 Q3 | 21.98 Million EUR | -35.11% |
| 2022 Q1 | 33.88 Million EUR | -6.55% |
| 2021 Q3 | 34.87 Million EUR | -2.42% |
| 2021 FY | 36.26 Million EUR | 33.27% |
| 2021 Q1 | 35.73 Million EUR | 31.34% |
| 2021 Q2 | 35.73 Million EUR | 0.0% |
| 2021 Q4 | 36.26 Million EUR | 3.99% |
| 2020 Q3 | 27.21 Million EUR | 44.37% |
| 2020 Q1 | 18.84 Million EUR | 6.93% |
| 2020 Q2 | 18.84 Million EUR | 0.0% |
| 2020 Q4 | 27.21 Million EUR | 0.0% |
| 2020 FY | 27.21 Million EUR | 53.97% |
| 2019 FY | 17.67 Million EUR | -19.17% |
| 2019 Q3 | 17.67 Million EUR | 19.16% |
| 2019 Q1 | 19.44 Million EUR | -11.05% |
| 2019 Q4 | 17.62 Million EUR | -0.25% |
| 2019 Q2 | 14.83 Million EUR | -23.74% |
| 2018 Q4 | 21.86 Million EUR | 0.0% |
| 2018 FY | 21.86 Million EUR | -15.74% |
| 2018 Q3 | 21.86 Million EUR | 2.72% |
| 2018 Q2 | 21.28 Million EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2017 Q4 | 25.94 Million EUR | 0.0% |
| 2017 FY | 25.94 Million EUR | 209.15% |
| 2017 Q1 | 10.26 Million EUR | 22.34% |
| 2017 Q2 | 10.26 Million EUR | 0.0% |
| 2017 Q3 | 25.94 Million EUR | 152.7% |
| 2016 Q1 | 11.19 Million EUR | -17.21% |
| 2016 Q4 | 8.39 Million EUR | 0.0% |
| 2016 FY | 8.39 Million EUR | -37.91% |
| 2016 Q3 | 8.39 Million EUR | -25.0% |
| 2016 Q2 | 11.19 Million EUR | 0.0% |
| 2015 Q3 | 13.54 Million EUR | 617.54% |
| 2015 Q1 | 1.88 Million EUR | 387.85% |
| 2015 FY | 13.51 Million EUR | 3393.95% |
| 2015 Q4 | 13.51 Million EUR | -0.19% |
| 2015 Q2 | 1.88 Million EUR | 0.0% |
| 2014 Q3 | 386.85 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 386.85 Thousand EUR | 0.0% |
| 2014 FY | 386.85 Thousand EUR | -38.38% |
| 2013 FY | 627.76 Thousand EUR | -48.11% |
| 2012 FY | 1.2 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 18.858% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 96.351% |
| Adocia SA | 24.95 Million EUR | 52.172% |
| Aelis Farma SA | 26.28 Million EUR | 54.583% |
| Advicenne S.A. | 12.4 Million EUR | 3.796% |
| genOway Société anonyme | 31.84 Million EUR | 62.515% |
| IntegraGen SA | 8 Million EUR | -49.193% |
| Medesis Pharma S.A. | 1.92 Million EUR | -519.622% |
| Neovacs S.A. | 47.53 Million EUR | 74.889% |
| NFL Biosciences SA | 3.97 Million EUR | -200.607% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 19.962% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -218.568% |
| Sensorion SA | 46.49 Million EUR | 74.328% |
| Theranexus Société Anonyme | 7.23 Million EUR | -64.913% |
| TME Pharma N.V. | 2.49 Million EUR | -379.165% |
| Valbiotis SA | 33.24 Million EUR | 64.1% |
| TheraVet SA | 7.53 Million EUR | -58.424% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 66.162% |
| argenx SE | 4.11 Billion EUR | 99.71% |
| BioSenic S.A. | 9.55 Million EUR | -24.867% |
| Celyad Oncology SA | 16.28 Million EUR | 26.692% |
| DBV Technologies S.A. | 165.65 Million USD | 92.794% |
| Galapagos NV | 4.35 Billion EUR | 99.726% |
| Genfit S.A. | 173.87 Million EUR | 93.135% |
| GeNeuro SA | 6.31 Million EUR | -89.073% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 74.967% |
| Innate Pharma S.A. | 184.19 Million EUR | 93.52% |
| Inventiva S.A. | 69.13 Million EUR | 82.736% |
| MaaT Pharma SA | 42.93 Million EUR | 72.197% |
| MedinCell S.A. | 36.94 Million EUR | 67.695% |
| Nanobiotix S.A. | 93.89 Million EUR | 87.288% |
| Onward Medical N.V. | 43.62 Million EUR | 72.642% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 88.834% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 85.426% |
| Oxurion NV | 6.55 Million EUR | -82.229% |
| Pharming Group N.V. | 426.33 Million EUR | 97.2% |
| Poxel S.A. | 4.82 Million EUR | -147.481% |
| GenSight Biologics S.A. | 9.08 Million EUR | -31.352% |
| Transgene SA | 45.21 Million EUR | 73.603% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.378% |
| UCB SA | 15.53 Billion EUR | 99.923% |
| Valneva SE | 469.39 Million EUR | 97.457% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 61.283% |